STOCK TITAN

Artelo Biosciences, Inc. - ARTL STOCK NEWS

Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.

Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.

Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.

One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.

Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.

Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.

Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.

Rhea-AI Summary

Artelo Biosciences presented comparative preclinical data on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium. Findings revealed ART12.11, a novel cannabidiol: tetramethylpyrazine cocrystal, has a unique pharmacokinetic profile, potentially superior to existing treatments for anxiety-related disorders. Research showed ART12.11 increased plasma levels of CBD in rodents and displayed efficacy in reducing anxiety and depressive symptoms. The drug demonstrated similar plasma levels of CBD as Epidiolex, suggesting its potential as an effective treatment. Artelo is currently optimizing ART12.11's oral delivery formulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) announced promising data from several research studies on its Fatty Acid Binding Protein 5 (FABP5) inhibitors at the ICRS Symposium, held June 30 – July 5, 2024, in Salamanca, Spain. The studies demonstrated the potential of FABP5 inhibitors in treating cancer, psoriasis, and anxiety disorders. ART26.12, one of Artelo’s lead inhibitors, showed anti-tumor effects in colon cancer models and potential for treating chemotherapy-induced peripheral neuropathy and psoriasis. Another inhibitor, SBFI103, improved depressive-like behaviors in preclinical studies. These findings support further development of FABP5 inhibitors, with first-in-human trials expected next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) presented preclinical data on ART26.12, a fatty acid-binding protein 5 (FABP5) inhibitor, at the 34th Annual International Cannabinoid Research Society Symposium. The data demonstrated ART26.12's effectiveness in reducing pain behaviors caused by breast cancer in preclinical studies. This study is the fourth in a series showing consistent efficacy in various pain models, including oxaliplatin-induced peripheral neuropathy. Artelo aims to initiate human trials following FDA approval of their Investigational New Drug application. Breast cancer often leads to bone metastasis, causing severe pain. ART26.12 offers a novel, non-opioid, non-steroidal treatment option for such pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, presented new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The conference took place from June 4-6, 2024, in Nottingham, UK. ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor, showed efficacy in reducing breast cancer-induced bone pain and diabetic neuropathy in preclinical models. Effective doses and plasma exposures were consistent with previous data. Artelo plans to submit an Investigational New Drug application to the U.S. FDA this month. This non-opioid, non-steroidal treatment is seen as a promising alternative for pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) presented new pre-clinical data on ART12.11 at the CT-CANN24 conference, demonstrating that ART12.11, a patented cocrystal of CBD and TMP, has comparable pharmacokinetics to Epidiolex in rats. Epidiolex, an FDA-approved oral CBD solution, saw over $845 million in net sales in 2023. ART12.11, in an unoptimized formulation, showed similar CBD levels in plasma to Epidiolex, suggesting potential for a solid dosage form that is preferred for adolescents and adults due to better dosing precision, storage, and transport. Previous animal studies indicated ART12.11 outperformed CBD in stress-induced anxiety and depression with a lower CBD amount. Artelo is developing an optimized tablet form of ART12.11 for clinical studies, aiming to broaden CBD research in larger populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences, Inc. (Nasdaq: ARTL) reported financial results for Q1 2024, highlighting progress in developing treatments for cancer, pain, dermatologic, and neurological conditions. The company's lead inhibitor, ART26.12, shows promise in treating neuropathic pain. Artelo's cash and investments stood at $7.6 million, with R&D expenses at $1.5 million and a net loss of $2.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
Rhea-AI Summary

Artelo Biosciences, Inc. (Nasdaq: ARTL) will be presenting at the 2024 Pharma Partnering Summit on May 14th, with CEO Gregory D. Gorgas discussing the company's focus on developing treatments for cancer, pain, dermatologic, and neurological conditions. The summit provides networking and partnership opportunities in the life sciences sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
conferences
-
Rhea-AI Summary
Artelo Biosciences announces the publication of a peer-reviewed article highlighting FABP7 as a promising novel target in cancer therapy. The article discusses the role of FABP7 in various cancers, its potential as a validated target in cancer treatment, and the impact of FABP7 inhibition on tumor growth and patient prognosis. Artelo is focused on developing FABP inhibitors for cancer and other serious conditions, with the lead compound ART26.12 showing promising results in preclinical studies for conditions like cancer bone pain and chemotherapy-induced peripheral neuropathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
Rhea-AI Summary
Artelo Biosciences CEO, Gregory D. Gorgas, will be a guest on Benzinga All Access on April 23rd at 10:50 AM Eastern Time. Artelo focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
Rhea-AI Summary
Artelo Biosciences, Inc. reports significant achievements in 2023, focusing on key milestones in cancer treatment development. The company completed phase 1b and initiated phase 2a of the Cancer Appetite Recovery Study (CAReS) with ART27.13, advanced ART 26.12 toward IND submission for neuropathic pain treatment, and presented data on the efficacy of ART12.11 in anxiety and depression models. The company also highlighted safety results for ART27.13, published research on its protective properties, and announced positive effects of ART26.12 in neuropathic pain models. Financially, Artelo Biosciences ended 2023 with $10.4 million in cash and investments, with R&D expenses at $5.7 million and a net loss of $9.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags

FAQ

What does Artelo Biosciences do?

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system.

Where is Artelo Biosciences headquartered?

Artelo Biosciences is headquartered in San Diego, California, with an additional office in Dublin, Ireland.

What are the main therapeutic areas Artelo Biosciences focuses on?

Artelo Biosciences focuses on developing treatments for anorexia, cancer, anxiety, pain, neuropathy, and inflammation.

What is ART12.11?

ART12.11 is Artelo’s proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP), which has shown improved bioavailability and efficacy compared to standard CBD compositions.

What is ART26.12?

ART26.12 is a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed by Artelo as a non-opioid, non-steroidal analgesic for treating chemotherapy-induced peripheral neuropathy (CIPN) and other neuropathic pains.

What is ART27.13?

ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors, currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial to improve body weight, appetite, and muscle degeneration in cancer patients.

What recent achievement has ART12.11 demonstrated?

ART12.11 has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone, providing better pharmacokinetics and efficacy.

What progress has been made in the ART26.12 program?

In preclinical studies, ART26.12 has shown efficacy in reducing pain in models of chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.

Who leads Artelo Biosciences?

Artelo Biosciences is led by experienced biopharmaceutical executives working in collaboration with highly respected researchers and technology experts.

Where can I find more information about Artelo Biosciences?

More information about Artelo Biosciences is available on their website, www.artelobio.com, and on Twitter @ArteloBio.

Artelo Biosciences, Inc.

Nasdaq:ARTL

ARTL Rankings

ARTL Stock Data

4.18M
3.23M
0.83%
0.77%
0.43%
Tobacco Manufacturing
Manufacturing
Link
United States of America
SOLANA BEACH